MedTrace Logo

Aromatase Inhibitor Growth Study: Letrozole vs. Anastrozole

NCT02137538 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 79

Last updated 2021-07-15

Study results available
· View outcomes & findings →

Summary

The purpose of the study is to determine if there are differences in the final height or hormone profile of short pubertal boys placed on different forms of aromatase inhibitor now routinely used to increase stature: Anastrozole and Letrozole. It also should determine if there are differences in the side effect profiles of the two drugs to be used.

Conditions

  • Short Stature

Interventions

DRUG

Letrozole

DRUG

Anastrozole

Sponsors & Collaborators

Principal Investigators

  • E Kirk Neely, MD · Stanford University

  • Laura K Bachrach, MD · Stanford University

  • Walter A Zegarra, MD · Stanford University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
10 Years
Max Age
17 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-11-18
Primary Completion
2018-06-05
Completion
2018-06-05

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02137538 on ClinicalTrials.gov